Coronary sinus reducer not beneficial in patients with ANOCA

In patients with refractory angina and coronary microvascular dysfunction but no obstructed coronary arteries, a coronary sinus reducer did not improve coronary microvascular function, symptoms and quality of life, researchers reported.
The single-center investigator-initiated REMEDY-PILOT trial, presented at TCT 2026, compared the performance of a coronary sinus reducer (Shockwave Reducer, Shockwave Medical) with a sham procedure at improving endocardial myocardial perfusion reserve, symptoms and quality of life.
“In patients undergoing investigation for angina with nonobstructed coronary

‘Bro science’ or breakthrough: Peptide craze hits orthopedics

On Oct. 28, 2026, HHS Secretary Robert F. Kennedy, Jr., released a draft enforcement policy that aims to expand and improve patient access to certain peptides through compounding pharmacies.
According to the policy, the HSS will not “take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a drug product using a peptide bulk drug substance” until it has been addressed in a final rule as being included or not included on the 503A bulk drug substances list. The enforcement policy notes it takes into account the recommendations from the FDA

Automated insulin delivery benefits type 1 and type 2 diabetes

Most people with type 1 or type 2 diabetes achieved target continuous glucose monitoring metrics while using the twiist automated insulin delivery system, according to real-world data.
In an analysis of 4,000 people with type 1 or type 2 diabetes using twiist (Sequel Med Tech), researchers found that most users were able to achieve a time in range with glucose of 70 mg/dL to 180 mg/dL of at least 70% and a time below range with glucose less than 70 mg/dL of lower than 4%. The data, which were published in Diabetes Technology & Therapeutics, were similar to what was observed in a

AD109 lowers OSA severity in post-menopausal women over 26 weeks

PHOENIX — Among post-menopausal women with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo achieved lower disease severity at 26 weeks, according to data presented here.
Additionally, improvements observed in this subgroup were greater than those reported in non-menopausal patients receiving AD109 (Apnimed), Reena Mehra, MD, MS, FCCP, head of the division of pulmonary, critical care and sleep medicine at the University of Washington Medical Center, said during the CHEST Annual Meeting presentation.
In an exploratory post hoc analysis of the

High specific IgE found in epinephrine-treated OIT reactions

Among preschool patients, baseline specific IgE was higher in those who received vs. did not receive epinephrine during oral immunotherapy, according to data published in The Journal of Allergy and Clinical Immunology: In Practice.
“We identified several characteristics most associated with reactions resulting in epinephrine administration, including older age, higher baseline food specific IgE, higher grade of initial reaction, comorbid allergic rhinitis and multi-food OIT,” Vicky Le Blanc, MD, FRCPC, clinical assistant professor in the division of allergy in the department of pediatrics at

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or metastatic gastroesophageal adenocarcinoma.
Findings from the randomized phase 3 HERIZON-GEA-01 trial, presented at European Society for Medical Oncology Congress, showed that zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) combinations extended median OS by 3 and 8 months.
“These results are truly ground-breaking and highlight how much the first-line treatment landscape for HER2-positive advanced gastroesophageal

Pancreatic cancer risk increases with worrisome cyst features

The presence of at least two “worrisome” features on pancreatic cystic lesions increases the risk for progression to cancer or high-grade dysplasia, approaching that of high-risk stigmata, according to results of a prospective cohort study.
“Pancreatic cysts are a common finding on imaging, and while most of these cysts will not go on to progress to cancer, there are cysts with worrisome and high-risk features that have a greater malignant potential,” study author Shounak Majumder, MD, associate professor of medicine at Mayo Clinic and vice chair of the pancreatic disorder section at AGA, told